Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Most Read

  1. Exscientia Q&A: leveraging AI to create bispecific small molecule drugs
  2. USPTO reverses decision regarding interfering CRISPR patents
  3. Veeva R&D summit: unifying across clinical, regulatory and quality suites
  4. Dassault to enhance clinical tech with $5.8bn Medidata acquisition
  5. ProAmpac updates child-resistant pouch product line

Company A-Z

Latest Content

QbD for Dummies

In recent times, the pharmaceutical and related industries have been challenged to think about the way they approach product development and manufacturing.

Life Sciences Manufacturing Transformation

Last year was a turning point for Life Sciences Manufacturing, with subjects such as Internet of Things (IoT), Industry 4.0, Digitalisation, cybersecurity and advanced analytics at the head of considerations.

Huber Again Invests in the Future

Peter Huber Kältemaschinenbau AG has marked the official construction commencement for another expansion of its headquarters in Offenburg-Elgersweier with a ground-breaking ceremony.

Exscientia Q&A: leveraging AI to create bispecific small molecule drugs

Creating bispecific small molecule drugs poses huge challenges, but Exscientia has successfully used AI to automate drug discovery and optimise drug design for these complex compounds. Exscientia’s CEO Andrew Hopkins discusses the importance of AI in overcoming development challenges and why targeting two targets simultaneously is efficacious in certain complex diseases.

Are M&As the Key to Securing Growth in the Orphan Drugs Sector?

The orphan drug market can be an alluringly lucrative sector. Most big pharma corporations inherit these specialty business units through mergers and acquisitions (M&As). Yet it is not a viable sector for all pharmaceutical companies as it requires specialist capabilities.

USPTO reverses decision regarding interfering CRISPR patents

The Patient Trial and Appeal Board (PTAB) of the US Patent and Trademark Office (USPTO) has changed its stance regarding an interference between ten patent applications from the University of California (UC) and 13 of the Broad Institute’s patents, as well as one patent application, related to CRISPR-Cas9 genome editing in eukaryotic cells.

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:


Go Top